Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957092 | 0.90 | PTGS1 (0.52) | GLO1PTGS1GSTK1NOD1 | |
| SCHEMBL4250989 | 0.89 | PTGS1 (0.47) | GLO1PTGS1GSTK1NOD1 | |
| SCHEMBL3721473 | 0.88 | PTGS1 (0.52) | GLO1PTGS1GSTK1NOD1 | |
| SCHEMBL9007888 | 0.86 | GLO1 (0.50) | GLO1PTGS1GSTK1NOD1KMT2A | |
| SCHEMBL4452894 | 0.86 | GLO1 (0.50) | GLO1PTGS1GSTK1NOD1KMT2A | |
| S-Nitrosoglutathione SCHEMBL17619393 | 0.85 | PTGS1 (0.67) | GLO1PTGS1GSTK1NOD1 | |
| S-Nitrosoglutathione SCHEMBL30637209 | 0.85 | PTGS1 (0.67) | GLO1PTGS1GSTK1NOD1 | |
| S-Nitrosoglutathione SCHEMBL1147641 | 0.85 | PTGS1 (0.67) | GLO1PTGS1GSTK1NOD1 | |
| S-Nitrosoglutathione SCHEMBL154575 | 0.85 | PTGS1 (0.67) | GLO1PTGS1GSTK1NOD1 | |
| S-Nitrosoglutathione SCHEMBL28090640 | 0.85 | PTGS1 (0.67) | GLO1PTGS1GSTK1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228520-A9 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240207265-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208979-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
| CN-117957228-A | SGC stimulators | 帝善多制药公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240132528-A1 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117915917-A | CNS disease treatment using sGC stimulators | 帝善多制药公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-3538096-B1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4326268-A1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | Tisento Therapeutics Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3762389-B1 | CRYSTALLINE FORMS OF AN SGC STIMULATOR | TISENTO THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20240059683-A1 | SOLID FORMS OF AN SGC STIMULATOR | CYCLERION THERAPEUTICS INC (US) | 2024-02-22 | — | — | US | disclosed |
| US-20080274547-A1 | USE OF NITRIC OXIDE MODULATORS IN AGROBACTERIUM-MEDIATED PLANT TRANSFORMATION | MONSANTO TECHNOLOGY LLC | 2008-11-06 | — | — | US | disclosed |
| WO-2008124505-A2 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS,INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-7388126-B2 | Such as NG-monomethyl-L-arginine, monoacetate salt; corn plants | MONSANTO TECHNOLOGY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060293265-A1 | Methods involving aldose reductase inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-12-28 | — | — | US | disclosed |
| US-20060210651-A1 | Methods and compositions involving aldose reductase | SRIVASTAVA SATISH K | 2006-09-21 | — | — | US | disclosed |
| US-20050155115-A1 | Use of Nitric Oxide Modulators in Agrobacterium-mediated Plant Transformation | MONSANTO TECHNOLOGY LLC (US) | 2005-07-14 | — | — | US | disclosed |
| WO-2003105864-A9 | METHODS AND COMPOSITIONS INVOLVING ALDOSE REDUCTASE INHIBITORS | UNIV TEXAS (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040047919-A1 | Methods and compositions involving aldose reductase inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-03-11 | — | — | US | disclosed |
| WO-2003105864-A1 | METHODS AND COMPOSITIONS INVOLVING ALDOSE REDUCTASE INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2002020834-A2 | METHOD FOR THE IDENTIFICATION OF GENES THAT ARE INVOLVED IN THE MODULATION OF A POPTOSIS IN CELLS | EIRX THERAPEUTICS LIMITED (IE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208979-A1 | sGC STIMULATORS | GMPS, PRKG1, CGAS | GLO1 400/4885PTGS1 42/4885GSTK1 495/4885 |
| US-20240059683-A1 | SOLID FORMS OF AN SGC STIMULATOR | GUCY1A2, PRKG1, GUCY1A1 | GLO1 391/4885PTGS1 33/4885GSTK1 426/4885 |
| US-20240228520-A9 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | P2RY1, P2RY11, GMPS | GLO1 3028/4885PTGS1 311/4885GSTK1 3602/4885 |
| US-20240132528-A1 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | P2RY1, P2RY11, GMPS | GLO1 3028/4885PTGS1 311/4885GSTK1 3602/4885 |
| US-20240207265-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1A1, GUCY1B2 | GLO1 927/4885PTGS1 59/4885GSTK1 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.